Organon rises on Q4 profit beat

Organon & Co.

13/02/2025 19:15

** Shares of healthcare company Organon  OGN.N  rise 11.2%
to $16.34
    ** The developer of drugs for women's health and biosimilars
posts Q4 adjusted profit of 90 cents per share vs analysts'
average estimate of 87 cents per share - data compiled by LSEG
    ** Q4 revenue at $1.59 billion, in line with the estimate
    ** "We expect a slightly positive stock reaction on Q4 EPS
beat and better EBITDA guidance, as the revenue guidance was
materially impacted by FX," says brokerage BNP Paribas Exane
    ** Company forecasts 2025 revenue in the range of $6.13
billion to $6.33 billion, below analysts' estimate of $6.47
billion
    ** OGN shares down ~3% in the last 12 months

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))